We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 103.00 | 9,948 | 08:00:02 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 102.00 | 104.00 | 104.00 | 103.00 | 103.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:43:16 | O | 516 | 102.12 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/4/2024 | 07:00 | UK RNS | Diaceutics PLC Appointment of Amie Mc Neice as VP of Marketing |
| 05/4/2024 | 13:40 | UK RNS | Diaceutics PLC Block Listing Return |
| 03/4/2024 | 07:00 | UK RNS | Diaceutics PLC PDMR Shareholding/Share Incentive Plan |
| 02/4/2024 | 19:02 | ALNC |  TRADING UPDATES: Roadside shares suspended; Adnams looks for funds |
| 02/4/2024 | 07:00 | UK RNS | Diaceutics PLC Director/PDMR/PCA Shareholding & TR1 |
| 21/3/2024 | 13:58 | ALNC | Diaceutics upgrades diagnositc commercialisation platform, DXRX |
| 21/3/2024 | 07:00 | UK RNS | Diaceutics PLC Significant upgrade to Diaceutics' DXRX platform |
| 19/3/2024 | 07:00 | UK RNS | Diaceutics PLC Diaceutics forms landmark industry Forum |
| 07/3/2024 | 07:00 | UK RNS | Diaceutics PLC Director/PDMR Shareholding |
| 01/3/2024 | 09:00 | UK RNS | Diaceutics PLC PDMR Shareholding / SIP and TVR |
Diaceutics (DXRX) Share Charts1 Year Diaceutics Chart |
|
1 Month Diaceutics Chart |
Intraday Diaceutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/4/2024 | 15:46 | DIACEUTICS SETS OUT STALL TO DOMINATE PRECISION MEDICINE TEST MARKET | 131 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:43:17 | 102.12 | 516 | 526.94 | O |
| 08:00:12 | 103.00 | 112 | 115.36 | UT |
| 07:32:34 | 103.00 | 2,967 | 3,056.01 | O |
| 07:08:28 | 103.30 | 2,500 | 2,582.50 | O |
| 07:01:13 | 103.50 | 3,853 | 3,987.85 | O |
| Top Posts |
|---|
Posted at 24/4/2024 09:20 by Diaceutics Daily Update Diaceutics Plc is listed in the Testing Laboratories sector of the London Stock Exchange with ticker DXRX. The last closing price for Diaceutics was 103p.Diaceutics currently has 84,472,431 shares in issue. The market capitalisation of Diaceutics is £87,006,604. Diaceutics has a price to earnings ratio (PE ratio) of 119.77. This morning DXRX shares opened at 103p |
Posted at 15/3/2024 07:26 by hastings Actually, not one of those is available on Research Tree which I also use. This is my point, the notes have been made available only to corporate clients and that is down to the broker as opposed to DXRX.That said, I agree with your point, it's a crying shame that they aren't more readily accessible, but ultimately in this case with many others it's down to the brokers. |
Posted at 15/3/2024 06:47 by hastings Wisecat2, it is wrong to say you can't look at the research unless you pay.Like many other quoted companies the brokers covering DXRX just don't make the info readily available to private investors.It isn't something I agree with as I believe in a level playing field, but it is unfortunately still quite common. I'm fortunate enough to have seen three of the notes including the most recent initiation from Panmure, all of which make for good reading. |
Posted at 15/3/2024 06:38 by wisecat2 Martin follows Filtronic. Have a look at the quality website and then look at DXRX and how cheap and out of date it is. Not good. Look at research no you cant unless you paynot a great way to attract new shareholders. Saying that it is an interesting company but needs to help potential investors, there a lot of cheap quality companies out there |
Posted at 25/7/2023 19:42 by 1c3479z wouldn't put it as strongly as that; there's many a company long expected to be taken over yet which has never received a bid...DXRX value might be in the data lake they hold except ?this is the property of the large pharmas so their real value could be in their client list and lab connections. |
Posted at 22/6/2023 07:47 by chrisdgb If it stays at this price, a takeover in the next year looks inevitable........ |
Posted at 21/4/2023 10:25 by tomps2 Diaceutics (DXRX) Full Year 2022 Results presentation - April 2023Diaceutics CFO, Nick Roberts & CIO Ryan Keeling present full year results for the period ended 31 December 2022, which shows a strong trading performance with continued momentum driving strategic investment into 2023. Watch the video here: Listen to the podcast here: |
Posted at 17/4/2023 11:33 by kalai1 Diaceutics PLC posted Finals for FY22 this morning titled "Strong trading performance with continued momentum driving strategic investment into 2023." Revenues increased 40% to £19.5 million, a 26% increase on a constant currency basis and materially ahead of initial expectations.Gross profit increased by 37% to £16.7 million, EBITDA was £3.6 million (2021: £2.3 million) with an EBITDA margin of 18%, slightly ahead of the prior year (2021: 17%). The outook is solid with order books up to £16.9 million, while the balance sheet is also strong with cash and cash equivalents of £19.8 million. Valuation looks a little unhelpful with PS ratio at around 5.5x, the share price also lacks positive momentum. DXRX has a solid track record of topline growth but is a share to monitor for the time being......from WealthOraacle |
Posted at 27/7/2022 19:17 by hedgehog 100 "DIACEUTICS TO BECOME FOURTH NORTHERN IRISH COMPANY LISTED ON LONDON STOCK EXCHANGERONAN LEONARD MARCH 18, 2019 Diaceutics plc, a revenue-generating, and profitable diagnostics data analytics and implementation services company which services the global pharmaceutical industry, today announces that it is seeking a listing on the AIM Market of the London Stock Exchange. This will make Diaceutics the fourth Northern Irish company currently listed on the London Stock Exchange. The company is expected to have a market capitalisation on admission of approximately £53M. ..." Rockpool Acquisitions (ROC) is a main-listed cash shell, which may be of interest to investors seeking other Northern Ireland investments to DXRX:- "A listed acquisition vehicle seeking opportunities in Northern Ireland. Northern Ireland has a good availability of high quality, often internationally-focu With extensive knowledge and experience of the Northern Ireland market, the directors are seeking to identify and acquire a highly ambitious, Northern Ireland-based company that is focused on significant growth, and provide it with that access, helping that company meet its aspirations and full potential. Target companies will have a valuation of up to £20m." Rockpool Acquisitions (ROC) 4.75p Market cap. £604K. ROC has about £950K. cash, and extremely low cashburn. ROC's large discount at the moment to its cash, despite this extremely low cashburn, looks like a temporary discrepancy - and one that is gradually being addressed by ROC's share price rise, as the market wakes up to the opportunity. |
Posted at 23/3/2022 08:37 by tomps2 Diaceutics (DXRX) full year 2021 results presentation March 2022Diaceutics Founder & CEO, Peter Keeling, and CFO, Nick Roberts, present full year results for the period ended 31 December 2021. These results show revenue increased 10% to £13.9m. Gross profit increased 13.4% to £10.7m. With a gross margin of 77%. Adjusted EBITDA was £2.3m and profit before tax £0.5m. Net cash £19.7m. Watch the video here: Or listen to the podcast here: |
Posted at 16/2/2022 18:07 by km18 ...from last month...Company overview:Diaceutics plc is involved in the provision of data analytics to assist pharmaceutical companies worldwide. Diaceutics is known for its robust pipeline development and concise diagnostic testing data conducted from a network of laboratories to find partners for collaboration on accurate medicine diagnostics. This plausible initiative enabled the firm to obtain a competitive advantage and thereby was incorporated into the firm’s financials prospects, where revenue grew 17% and EBITDA leapt to £2.1m from £0.5m. Despite the favourable corporate news, the firm is expected to experience an additional 29% growth in revenue during 2022, illustrated by its CAGR rate....from WealthOracleAM |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
